Systemic Safety and Neuroprotective Potential of Chronic ∆9-THCA-Enriched Extract Administration: Divergent Effects on Molecular Neuroprotection and Physical Endurance in Aging Models
Pharmaceuticals · 07.11.2026 · 19 (11) · 1770
DOI: 10.3390/ph19111770 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 07.11.2026. Verfasst von Ivona Maria Tudorancea und 13 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Grigore T. Popa" Universty of Medicine and Pharmacy.
Abstract (Originalsprache)
Background
Aging is characterized by inflammaging, a progressive decline in metabolic homeostasis, and increased neuroinflammation. While the endocannabinoid system (ECS) regulates these processes, its tone diminishes with age. This study investigated the systemic safety and therapeutic potential of a full-spectrum, ∆9-THCA-enriched Cannabis extract in naturally aged rats.
Methods
Aged Sprague–Dawley rats received intermittent oral doses (5 days on/2 days off) of a ∆9-THCA-enriched extract (0.5, 1.0, and 2.0 mg/kg) for six weeks. Assessments included body weight monitoring, physical endurance (treadmill), and neuromotor coordination (rotarod). Post-mortem evaluations encompassed systemic histopathology, serum biochemistry, and hippocampal immunohistochemistry for microglial (Iba-1), astrocytic (GFAP), and apoptotic (caspase-3) markers.
Results
The extract demonstrated excellent systemic safety, with hepatic and renal markers remaining within physiological ranges. Treatment significantly attenuated age-related weight loss, with the 2.0 mg/kg dose achieving the most robust preservation (p < 0.001). In the hippocampus, the extract induced a reversal of neuroinflammation mediated by Iba-1, reducing Iba-1-positive microglial density by 93.5–97.9% across all doses (p < 0.001). Although the reduction was substantial at all doses, greater inter-individual variability was observed in the OLD-0.5 group. The extract also significantly attenuated apoptotic signaling (p = 0.029). Conversely, a dose-dependent reduction in peak physical endurance was observed, driven by increased task refusal rather than neuromotor impairment. Principal Component Analysis confirmed a phenotypic shift toward metabolic and neuroinflammatory stability at the cost of maximal aerobic power.
Conclusions
Chronic intermittent administration of a ∆9-THCA-enriched extract reconfigures the aged phenotype, prioritizing metabolic maintenance and neuroprotection. These findings suggest full-spectrum cannabinoids serve as a viable geroprotective for neuroinflammatory stress, although their functional impact warrants careful consideration in the context of frailty.
Förderung
- "Grigore T. Popa" Universty of Medicine and Pharmacy
Zitieren
APA
Tudorancea, I. M., Ciorpac, M., Alexa-Stratulat, T., Davidson, M., Solcan, C., Stanciu, G., Filipiuc, L., Mazarianu, I., Ababei, D., Gogu, R., Szilagyi, A., Roman, C., Timofte, A., & Tamba, B. (2026). Systemic Safety and Neuroprotective Potential of Chronic ∆9-THCA-Enriched Extract Administration: Divergent Effects on Molecular Neuroprotection and Physical Endurance in Aging Models. Pharmaceuticals, 19(11), 1770. https://doi.org/10.3390/ph19111770
Vancouver
Tudorancea IM, Ciorpac M, Alexa-Stratulat T, Davidson M, Solcan C, Stanciu G, et al. Systemic Safety and Neuroprotective Potential of Chronic ∆9-THCA-Enriched Extract Administration: Divergent Effects on Molecular Neuroprotection and Physical Endurance in Aging Models. Pharmaceuticals. 2026;19(11):1770. doi:10.3390/ph19111770
BibTeX
@article{Tudorancea2026,
author = {Tudorancea, Ivona Maria and Ciorpac, Mitica and Alexa-Stratulat, Teodora and Davidson, Michael and Solcan, Carmen and Stanciu, Gabriela-Dumitrița and Filipiuc, Leontina-Elena and Mazarianu, Ivona and Ababei, Daniela-Carmen and Gogu, Raluca-Maria and Szilagyi, Andrei and Roman, Constantin and Timofte, Andrei-Daniel and Tamba, Bogdan-Ionel},
title = {Systemic Safety and Neuroprotective Potential of Chronic ∆9-THCA-Enriched Extract Administration: Divergent Effects on Molecular Neuroprotection and Physical Endurance in Aging Models},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1770},
doi = {10.3390/ph19111770}
}
EUVIMED